CITIUS ONCOLOGY, INC. (CTOR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US17331Y1091
CITIUS ONCOLOGY, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -23.52 m USD |
| EBIT | -23.52 m USD |
| Net income | -24.76 m USD |
| Diluted EPS – continuing operations | -0.34 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CITIUS ONCOLOGY, INC.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
More stocks
- FPX Nickel Corp (FPX.V)
- Skardin Industrial (3466.TWO)
- PT Mulia Industrindo Tbk (MLIA.JK)
- Pungguk Ethanol Industrial Co. Ltd (023900.KQ)
- Protech Mitra Perkasa Tbk PT (OASA.JK)
- Richmond International Travel & Tours Co Ltd (2743.TWO)
- CPI AEROSTRUCTURES INC (CVU)
- Asia File Corporation Bhd (7129.KL)
- Hyweb Technology Co Ltd (5212.TWO)
- Airtasker Ltd (ART.AX)
- Forcera Materials Co., Ltd. (3467.TWO)
- Wonder Pets Enterprises Corporation (6968.TWO)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.